We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Microplastics and Nanoplastics in Human Blood: Current Evidence, Practical Measurement Limitations, and the Need for Scalable Tests for Public Health Studies and Routine Clinical Use
Summary
Scientists have confirmed tiny plastic particles (microplastics and nanoplastics) are showing up in human blood, but this review shows that different labs use very different testing methods, making it hard to compare results or track how plastic exposure might affect our health over time. That matters because without a standardized, reliable blood test, we can't yet answer basic questions like how much plastic is in our bodies, whether it's increasing, or what health risks it poses, though the researchers highlight a new testing approach in development that could help solve this problem.
Microplastics (MPs) and nanoplastics (NPs) have now been reported in human blood using multiple analytical approaches, including pyrolysis–gas chromatography/mass spectrometry (Py-GC/MS), micro-Fourier transform infrared spectroscopy (µFTIR), Raman-based methods, fluorescence imaging, and Nile Red-based flow cytometry. Published studies collectively support the presence of plastic-associated material in human circulation, but they do not yet constitute a standardized blood-testing framework. Existing methods differ substantially in sample preparation, specimen volume, particle-size sensitivity, analytical output, workflow duration, and whether results are reported as polymer mass, individually characterized particles, or fluorescent events. These differences limit direct comparisons across studies and create substantial challenges for translation to longitudinal human exposure monitoring. This review examines published approaches for detecting MPs and NPs in human blood, with particular attention to their practical workflows and analytical outputs. It distinguishes instrument acquisition time from total sample-to-result time, examines limitations associated with small-volume blood sampling and dried-blood approaches, and discusses the implications of Poisson sampling when discrete particles are measured in small biological aliquots. A particle-based optical approach under development by ecotera health is presented as an emerging strategy intended to provide results for public health studies and routine clinical use.